General Mills sticks to 2024 outlook as inflation slows down and consumers grow 'increasingly cautious'
General Mills Inc. (GIS) said Wednesday it continues to expect fiscal 2024 organic net sales to grow by 3% to 4% as it navigates a "resilient but increasingly cautious consumer" in the marketplace. CEO Jeff Harmening said the company will continue adapting to the changing environment with a focus on supply chain efficiency and disciplined capital allocation. Retail sales in the first quarter for at-home food categories in the U.S. continue to grow above pre-pandemic rates in but have slowed down from double-digit growth rates in fiscal 2023 as the company faces "increased value-seeking behaviors from consumers." General Mills provided the comments ahead of its presentation at the 2023 Barclays Global Consumer Staples Conference. Shares of General Mills were up 1.2% in premarket trades on Wednesday. The stock is down 21% so far in 2023, compared to a 17.1% increase by the S&P 500 .
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-06-23 0756ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks